ArticleBMC women's health2026
Atherogenic lipid indices and metabolic syndrome in polycystic ovary syndrome: a comparative cross-sectional study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic Ovary Syndrome (PCOS) is one of the causes of infertility in females. It is also associated with hyperandrogenism and hyperinsulinemia. With these hormonal imbalances, there can be an equally important risk of cardiometabolic consequences as a result of altered atherogenic lipid indices and metabolic syndrome which has not been much explored in context of Nepal. The purpose of this study was to delve into different lipid profile parameters to calculate atherogenic lipid indices to identify the metabolic syndrome (MetS) and cardiovascular risk in PCOS.
methodsWe enrolled 70 PCOS and 60 age-matched non-PCOS females visiting the Infertility Clinic at the Department of Obstetrics and Gynecology at Tribhuvan University Teaching Hospital. After written informed consent, anthropometric measurements as well as a blood samples were taken and biochemical analysis of glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were measured in Abbott ARCHITECT ci4100 autoanalyzer. Based on the examined variables, various formulas to assess atherogenic risk and metabolic syndrome [Castelli's risk index I & II (CRI-I, CRI-II), atherogenic coefficient (AC), atherogenic index of plasma (AIP), lipoprotein combined index (LCI), lipid accumulation product (LAP)] were applied. Descriptive and inferential analysis was carried in SPSS version 23.0. A p-value ≤ 0.05 was considered as significant.
resultsThe PCOS group had higher atherogenic lipid indices (CRI-I, CRI-II, AIP, AC, LCI and LAP) compared to their non-PCOS counterparts. The prevalence of metabolic syndrome (MetS) was also higher in the PCOS (81.4%, n = 57) compared to non-PCOS (30%, n = 18). The LAP score was found to be an efficient indicator of MetS in the PCOS patients with an AUC of 0.829 (p < 0.001), with the sensitivity and specificity of 80% and 94.5% respectively.
conclusionsOur study showed a higher frequency of MetS and cardiovascular risk in PCOS as determined by higher atherogenic lipid indices than non PCOS. LAP score was the most efficient indicator of MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.